Positive changes in ALS gene expression and increased cellular viability met with statistical significance of p<.001
NEW YORK, Sept. 7, 2023 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq:SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing therapeutics for neurodegenerative disorders, today announced findings from an independent study demonstrating the potential for Bryostatin-1 as a treatment strategy for amyotrophic lateral sclerosis ("ALS"), also known as Lou Gehrig's Disease.
Read more at prnewswire.com